Business
Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin
HOUSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that an abstract featuring pooled cardiac safety data for its lead drug candidate Annamycin (also known as “L-Annamycin” or “naxtarubicin”), has been accepted for poster presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026, in Chicago, Illinois. Access the abstract here. The abstract, titled “Cardiac
About this update from Moleculin Biotech, Inc.
[{"type":"image","alt":"Moleculin Biotech, Inc.","displaySize":"","headline":null,"caption":"Moleculin Biotech, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":113,"url":"https://media.zenfs.com/en/globenewswire.com/6b5ac38e783ff6d5136647894faf0cc3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ygVdJytEJhyRWCgJ6Op6NA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1OA--/https://media.zenfs.com/en/globenewswire.com/6b5ac38e783ff6d5136647894faf0cc3","width":300,"height":113},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/ygVdJytEJhyRWCgJ6Op6NA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1OA--/https://media.zenfs.com/en/globenewswire.com/6b5ac38e783ff6d5136647894faf0cc3","width":300,"height":113}},"lazy":false},{"type":"text","content":"HOUSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that an abstract featuring pooled cardiac safety data for its lead drug candidate Annamycin (also known as “L-Annamycin” or “naxtarubicin”), has been accepted for poster presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026, in Chicago, Illinois. Access the abstract here.","length":469,"tagName":"p"},{"type":"text","content":"The abstract, titled “Cardiac safety of L-annamycin at high cumulative anthracycline exposure: Pooled analysis,” will be presented in a poster session focused on Symptom Science and Palliative Care.","length":198,"tagName":"p"},{"type":"text","content":"Presentation Details:","length":21,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Session Type: Poster Session - Symptom Science and Palliative Care","length":66,"tagName":"p"}]},{"val":[{"type":"text","content":"Presentation Date and Time: May 30, 2026, 1:30 PM – 4:30 PM CDT","length":63,"tagName":"p"}]},{"val":[{"type":"text","content":"Location: Poster Board #8 ","length":25,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":154,"olType":false},{"type":"text","content":"The abstract presents pooled cardiac safety analyses from sponsor- and investigator-initiated clinical trials evaluating Annamycin (also known as “L-Annamycin” or “naxtarubicin”) in patients with acute myeloid leukemia (AML) and soft tissue sarcoma.","length":249,"tagName":"p"},{"type":"text","content":"Key findings inc...